Quality of care for hypertension in the United States by Asch, Steven M et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cardiovascular Disorders
Open Access Research article
Quality of care for hypertension in the United States
Steven M Asch*1,2, Elizabeth A McGlynn2, Liisa Hiatt2, John Adams2, 
Jennifer Hicks2, Alison DeCristofaro2, Roland Chen3, Pablo LaPuerta3 and 
Eve A Kerr4
Address: 1West LA VA, Mail Code 111G, 11301 Wilshire Bl, Los Angeles, CA 90073, USA, 2RAND Health, 1776 Main Street, Santa Monica, CA 
90407, USA, 3Global Epidemiology and Outcomes Research, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, PO Box 4000, 
Princeton, NJ 08543-4000, USA and 4VA Center for Practice Management and Outcomes Research and the Department of Medicine, University of 
Michigan, Ann Arbor, (11H), 2215 Fuller Road, Ann Arbor, MI 48105, USA
Email: Steven M Asch* - sasch@rand.org; Elizabeth A McGlynn - mcglynn@rand.org; Liisa Hiatt - hiatt@rand.org; 
John Adams - adams@rand.org; Jennifer Hicks - jennifer.Curtis@wellpoint.com; Alison DeCristofaro - hardy@rand.org; 
Roland Chen - roland.chen@bms.com; Pablo LaPuerta - pablo.lapuerta@bms.com; Eve A Kerr - ekerr@umich.edu
* Corresponding author    
Abstract
Background: Despite heavy recent emphasis on blood pressure (BP) control, many patients fail
to meet widely accepted goals. While access and adherence to therapy certainly play a role,
another potential explanation is poor quality of essential care processes (QC). Yet little is known
about the relationship between QC and BP control.
Methods:  We assessed QC in 12 U.S. communities by reviewing the medical records of a
randomly selected group of patients for the two years preceding our study. We included patients
with either a diagnosis of hypertension or two visits with BPs of ≥140/90 in their medical records.
We used 28 process indicators based on explicit evidence to assess QC. The indicators covered a
broad spectrum of care and were developed through a modified Delphi method. We considered
patients who received all indicated care to have optimal QC. We defined control of hypertension
as BP < 140/90 in the most recent reading.
Results: Of 1,953 hypertensive patients, only 57% received optimal care and 42% had controlled
hypertension. Patients who had received optimal care were more likely to have their BP under
control at the end of the study (45% vs. 35%, p = .0006). Patients were more likely to receive
optimal care if they were over age 50 (76% vs. 63%, p < .0001), had diabetes (77% vs. 71%, p =
.0038), coronary artery disease (87% vs. 69%, p < .0001), or hyperlipidemia (80% vs. 68%, p <
.0001), and did not smoke (73% vs. 66%, p = .0005).
Conclusions: Higher QC for hypertensive patients is associated with better BP control. Younger
patients without cardiac risk factors are at greatest risk for poor care. Quality measurement
systems like the one presented in this study can guide future quality improvement efforts.
Background
Hypertension affects approximately 58 million Americans
[1]. Lowering diastolic blood pressure (BP) by 10 mm Hg
can reduce the number of strokes by as much as 56% and
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the incidence of coronary heart disease by 37% [2]. In
addition, it has been shown that lowering systolic BP to
150 mm Hg decreases the incidence of all types of strokes
[3]. Although treatment reduces mortality, morbidity and
costs, nearly half of all people with hypertension go
untreated and only 23% control their BP to the recom-
mended level [4]. The high prevalence of uncontrolled
hypertension is due in part to a lack of awareness: 32% of
people with the disease do not know they have it [4].
However, over 40% of diagnosed hypertensive patients
remain uncontrolled [4].
One potential explanation for uncontrolled hypertension
is suboptimal quality of care. Although the U.S. Joint
National Committee on Prevention, Detection, and Treat-
ment of High Blood Pressure (JNC-VII) [5] has codified
standards for clinical processes in hypertension in the
United States, studies dating back to the 1970s have
shown that many patients fail to receive this essential care
[6-8]. On the other hand, many of these studies have not
established a relationship between these care processes
and BP control. One exception is a recent study of U.S.
Veterans Administration patients in five facilities, which
found a correlation between aggressive treatment and bet-
ter-controlled BP [9]. Still, most studies examining the
link between care processes and controlled hypertension
generally have been confined to single delivery systems, a
limited number of facilities, or a relatively small set of
indicators of hypertensive quality. In a previous study, we
examined general measures of hypertensive quality
(including treatment, diagnosis, and follow-up indica-
tors) and found that these care processes were associated
with BP control in young women participating in a single
health plan [10]. Studies with more generalizable target
populations are lacking.
If deficits in process quality are indeed related to BP con-
trol, then which patients are failing to receive optimal
care? The literature suggests that ethnic minorities and
older patients are less likely to have controlled hyperten-
sion [4], but we do not know what clinical factors may be
affecting patient care. For instance, physicians may be tar-
geting higher-risk patients and administering better care
to those with diabetes, coronary artery disease (CAD), and
tobacco abuse. Likewise, providers may be delivering bet-
ter care to older patients as they are also at higher risk,
though limited evidence suggests the opposite is true
[11,12].
We hypothesized that overall process quality for hyperten-
sive care is associated with better BP control. We devel-
oped indicators of hypertensive care and determined
whether patients had received the indicated care by
reviewing medical records for a national sample of
patients receiving care in a variety of settings. We also
investigated whether patients with other cardiac risk fac-




Our examination of hypertensive care was part of a larger
study called the Community Quality Index Study (CQI),
a cross-sectional study that assessed effectiveness of care
for 32 different clinical conditions by examining medical
records for patients in 12 randomly selected communities
with populations greater than 200,000 (Boston, Cleve-
land, Greenville, Indianapolis, Lansing, Little Rock,
Miami, Newark, Orange County, Phoenix, Seattle, and
Syracuse) [13]. The methodology and overall results from
CQI are presented elsewhere, and are summarized briefly
here [14]. Between October 1998 and August 2000, study
participants were selected by random digit dialing and
asked permission to obtain copies of their medical records
from all providers they had seen in the previous two years
[14]. Of the 20,158 persons in the starting sample, we
excluded 2,091 (10%) because they had moved out of the
area, passed away, or become incapacitated in some man-
ner that left them unable to participate in the study. Of the
17,937 adults who were eligible for the study, 74%
(13,275) completed the telephone survey. Of the 12,412
participants who reported having at least one health care
visit during the previous two years, 84% (10,404) agreed
to medical record review and 7,528 signed consent forms.
We obtained at least one record for 89% (6,712) of the
respondents who consented, and we received 84% of the
total records for which we had consent forms. Non-
respondents were more likely to be female, older, and to
have used health care services during the study period (p
< .001).
Development of quality indicators
We developed process indicators for hypertensive quality
of care by reviewing the scientific literature and clinical
practice guidelines [15] pertaining to hypertensive care
[16,17]. The indicators represented clinical processes
across the spectrum of hypertensive care and were based
closely on JNC-VI [15]. A diverse expert panel of nine phy-
sicians reviewed the indicators and supporting evidence
using a modified Delphi method. They rated each indica-
tor's feasibility and validity using a 9-point Likert scale.
Indicators were accepted if their median validity score was
7 or higher and their median feasibility score was 4 or
higher. The final 28 quality-of-care indicators included 1
screening indicator, 14 diagnostic indicators, 8 treatment
indicators, and 5 follow-up indicators. Eight of the indica-
tors were supported by randomized controlled trials and
20 by JNC-VI or other expert guidelines. The full list of
indicators is presented in Table 1.BMC Cardiovascular Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2261/5/1
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Table 1: Performance of recommended hypertensive care indicators
Indicator Eligible (n) Adherence to 
Indicators (%)
Standard Error (%)
1. Systolic and diastolic blood pressure should be measured 
on patients otherwise presenting for care at least once each 
year.
1,953 72 1.0
2. All patients with average blood pressures of Stage 1 or 
greater as determined on at least 3 separate visits should have 
a diagnosis of hypertension documented in the record.
823 73 1.8
3. Patients with a new diagnosis of Stage 1–3 hypertension 
should have at least 3 or more measurements on separate 
visits with a mean SBP > 140 or a mean DBP > 90.
185 21 3.6
4. Medication and substance abuse: Personal history of 
tobacco abuse, alcohol abuse, or taking of medications that 
may cause hypertension;
183 35 5.0
5. Physical examination: examination of the fundi 199 14 2.8
6. Examination of heart sounds 199 71 4.1
7. Examination of abdomen for bruits 199 49 4.6
8. Examination of peripheral arterial pulses 199 32 4.1
9. Examination of neurologic system 199 35 4.6
10. Initial laboratory tests should include at least 5 of the 
following: Urinalysis;
241 30 4.3
11. Serum, plasma, or blood glucose; 241 65 4.2
12. Serum potassium; 241 59 4.4
13. Serum creatinine; 241 62 4.2
14. Serum cholesterol; or 241 58 4.2
15. Serum triglyceride. 241 60 4.4
16. First-line treatment for patients in risk group HN-A or 
HN-B, is lifestyle modification. The medical record should 
indicate counseling for at least 1 of the following 
interventions prior to initiating pharmacotherapy:
27 31 10.2
- weight reduction if obese;
- increased physical activity if sedentary; or
- low sodium diet.
17. First-line treatment for patients with Stage 1A 
hypertension, is lifestyle modification. The medical record 
should indicate counseling for at least 1 of the following 
interventions prior to initiating pharmacotherapy:
25 25 10.4
- weight reduction if obese;
- increased physical activity if sedentary; or
- low sodium diet.
18. Treatment for Stage 1B and 1C, and Stages 2 and 3 
hypertension should include lifestyle modification. The 
medical record should indicate counseling for at least 1 of the 
following interventions:
149 40 5.3
- weight reduction if obese;
- increased physical activity if sedentary; or
- low sodium diet.
19. Stage 1B hypertensives whose blood pressure remains 
Stage 1 after 6 months of lifestyle modification 
recommendation should be offered pharmacotherapy.
113 20 4.5
20. Stage 1A hypertensives whose blood pressure remains 
Stage 1 after 12 months of lifestyle modification 
recommendation should be offered pharmacotherapy.
22 14 7.6
21. Patients in any risk group with Stage 2–3 hypertension 
should be offered pharmacotherapy.
359 64 3.4
22. Patients in Risk group HN-C should be offered 
pharmacotherapy.
277 67 3.9
23. Patients in Risk group C with stage 1 hypertension should 
be offered pharmacotherapy.
332 75 2.9BMC Cardiovascular Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2261/5/1
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Data collection
After a two-week training course, twenty nurse abstractors
used a computer-based abstraction tool with branching
logic to abstract from the medical records we collected the
following data for the two-year study period: a diagnosis
of hypertension; a diagnosis of co-morbid disease, includ-
ing CAD, diabetes, and hyperlipidemia; BP readings; lab-
oratory results, including serum creatinine, cholesterol,
trigylcerides, sodium, potassium, and urinalyses; prescrip-
tions for anti-hypertensive agents; and counseling for life-
style modification. The Kappa statistic for inter-rater
reliability for indicator eligibility was .75 and, given agree-
ment on eligibility, the kappa statistic for the indicated
care was .91.
Definitions
86% of patients with a visit in the last 13 months of the
study period had a blood pressure measured. Patients
were included in the study if their provider noted a diag-
nosis of hypertension in their medical record or if they
had BP readings greater than 140/90 on two occasions at
least two weeks apart. However, patients were only classi-
fied as having a new diagnosis of hypertension if this was
specifically noted in their medical records. Per JNC-VI, we
defined Stage 1 hypertension as BP 140/90–159/99 and
Stage 2 hypertension as BP > 160/100; we determined
stage by averaging a patient's BP over the study period,
regardless of notation of diagnosis or treatment regimen.
We defined uncontrolled hypertension as a last systolic BP
≥ 140 or a last diastolic BP ≥ 90.
Analytic methods
We determined both individual and overall quality scores
for each patient. We calculated individual scores by deter-
mining a patient's eligibility for an indicator and whether
s/he received the indicated care. We calculated overall
quality scores by adding the number of instances in which
a patient was eligible for and received the indicated care
and dividing this number by the total number of instances
for which s/he was eligible for the indicated care; this
score was expressed as a percentage. We defined optimal
quality as patients having received all of the indicated care
for which they were eligible. We adjusted the scores for
non-response using multivariate models that weighted
respondents to be representative of the population from
which they were drawn. We used the bootstrap method to
directly estimate standard errors for all of the individual
indicator scores [18]. Statistical comparisons at the bi-var-
iate level were reported as t-tests for continuous variables
and chi-square tests for categorical discontinuous varia-
bles. A multivariate regression model was constructed to
explain BP control using clinical and demographic varia-
bles available from the medical record.
Results
Of the 6,712 adult patients for whom we analyzed medi-
cal records1,953 (29%) had a diagnosis of hypertension
noted in their medical record or repeated BP readings
indicative of hypertension. Of these, 241 (12%) were
newly diagnosed during the study period; 1,102 (57%)
had hypertension noted in the medical record, but the
diagnosis was not new; 610 (31%) had repeated BPs ≥
140 systolic and/or 90 diastolic evidencing hypertension,
but no diagnosis in the chart. The sample included 1,070
women (55%), 1,326 patients over age 50 (68%), and
918 (47%) patients with CAD, hyperlipidemia, or diabe-
tes noted in their medical records. The average last systolic
BP was 139.2 and the average last diastolic BP was 82.0.
Of the 1,368 patients (70%) who were receiving pharma-
cological treatment for hypertension, 25% were pre-
scribed beta-blockers, 37% diuretics, 30% calcium
channel blockers, and 35% angiotensin converting
24. Hypertensive patients should visit the provider at least 
once each year.
1,681 94 0.7
25. Newly diagnosed Stage 1 patients should be evaluated by 
the provider within 4 months of their initial visit.
111 76 5.1
26. Newly diagnosed Stage 2 patients should be evaluated by 
the provider within 2 months of their initial visit.
56 66 7.6
27. Newly diagnosed Stage 3 patients should be evaluated by 
the provider within 2 weeks of their initial visit.
18 33 12.9
28. Hypertensive patients with consistent average SBP > 140 
or DBP > 90 over 6 months should have one of the following 
interventions recorded in the medical record:
853 77 1.8
- Change in dose or regimen of antihypertensives; or
- Repeated education regarding lifestyle modifications.
Overall 72 1.0
Explanation of staging system used in Table 1 Risk group A indicates no CAD risk factors or target organ damage or CAD. Risk group B 
indicates CAD risk factors, but no target organ damage or CAD or DM. Risk group C indicates target organ damage, DM or CAD. HN high-normal 
indicates 130–139 or 85–89. Stage 1 hypertension indicates 140–159 or 90–99. Stage 2 hypertension indicates 160–179 or 100–109. Stage 3 
hypertension indicates ≥180 or ≥110.
Table 1: Performance of recommended hypertensive care indicators (Continued)BMC Cardiovascular Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2261/5/1
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enzyme inhibitors or angiotensin II receptor antagonists.
Patients with a diagnosis of hypertension noted in their
records were more likely to have received pharmacother-
apy during the study period than those with elevated BP
readings but no notation of a diagnosis (88% vs. 31%, p
< .0001).
On average, patients were eligible for 3.8 indicators
(range: 1–21 and visited their providers 13 times during
the study period. Table 1 shows the performance of the 28
indicators among the sample. Indicator #1 had the largest
number of eligible patients (n = 1,953); Indicator # 27
had the fewest number of eligible patients (n = 20). Indi-
cator scores ranged from a low of 14% for Indicators #5
and #20 to a high of 94% for Indicator #24. Indicator #28
required a change in regimen in response to persistently
elevated blood pressure; 80% of patients satisfied this
requirement with a change in medication and 20% with
repeated counseling on nonpharmacologic means of BP
control. The mean patient overall quality score was 72%,
and 57% of patients (1,113) received optimal quality of
care (i.e., they received all recommended care for which
they were eligible). The overall quality score was higher
for patients with a diagnosis of hypertension noted in
their chart (86% vs. 41%, p < .0001).
The last BP reading for 42% (825) of patients indicated
good control (<140/90). Table 2 shows the proportion of
patients with well-controlled BP who received optimal
and sub-optimal care by subgroup. Overall, patients with
optimal quality care were more likely to have their BP
under control (44.9% vs. 35.1%, p < .0006). This held
true for all age groups, and for men, but was not statisti-
cally significant for women. Patients with optimal quality
scores who did not have diabetes, CAD, or hyperlipidemia
were more likely to have their BP controlled than those
with sub-optimal scores.
A logistic regression (not shown) revealed that the rela-
tionship between higher quality scores and BP control
persisted when controlling for number of physician visits,
baseline blood pressure control, gender, age, smoking sta-
tus, and presence of CAD, diabetes, or hyperlipidemia.
Other than quality, only baseline BP control was signifi-
cantly associated with BP control at the end of the study.
The relationship between quality and BP control also per-
sisted when we restricted the study sample to those with
at least two BP readings 12 months apart (n = 1,321).
Likewise, there were no changes in direction or signifi-
cance when we controlled for BP at 160/100 or used the
continuous measures of last systolic or diastolic BP read-
ing as the outcome.
Figure 1 shows the relationship between quality scores
and various demographic and clinical characteristics.
There was no significant difference between quality for
men and women; however, patients over age 50 received
better care than their younger cohorts (76% vs. 63%, p =
<.0001), as did patients with diabetes (77% vs. 71%, p =
.0038), CAD (87% vs. 69%, p = <.0001), or hyperlipi-
demia (80% vs. 68%, p = <.0001). In addition, smoking
was associated with lower quality of care (66% vs. 73%, p
= .0005).
Discussion
Our data suggest that quality of care for hypertensive
patients falls short of the ideal. Overall, patients received
about 72% of recommended essential care processes, and
Table 2: Proportion of patients with well controlled BP by level of quality of care received
Group N % <140/90 (Standard error) P-value
Optimal quality Sub-optimal quality
All 1,953 44.9 (2.0) 35.1 (2.0) .0006
Female 1,070 41.2 (2.5) 37.5 (2.7) .3209
Male 883 48.9 (2.8) 32.7 (3.0) .0001
Age <= 50 627 49.5 (3.4) 39.1 (3.0) .0234
Age > 50 1,326 43.4 (2.4) 32.2 (2.7) .0020
Diabetes 372 48.5 (3.7) 43.9 (5.4) .4797
No diabetes 1,581 44.0 (2.2) 33.5 (2.2) .0008
CAD 337 43.6 (3.9) 38.4 (6.3) .4835
No CAD 1,616 45.3 (2.3) 34.8 (2.1) .0007
Hyperlipidemia 604 47.4 (3.3) 39.7 (4.2) .1496
No hyperlipidemia 1,349 43.5 (2.4) 33.7 (2.3) .0033
CAD, DM, or 
hyperlipidemia
918 46.2 (2.7) 41.9 (3.5) .3237
Smoker 352 47.6 (4.7) 37.9 (4.1) .1218
Nonsmoker 1,601 44.4 (2.1) 34.3 (2.4) .0015BMC Cardiovascular Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2261/5/1
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77% of patients with persistently elevated blood pressure
had some change in therapy noted in the medical record
over the course of two years. Though still concerning,
these rates are higher than in some previous studies in
more limited populations [9,19]. Some of the differences
may be due to differences in the study population, and
some may be due to more liberal definitions of what con-
stitutes a change in therapy. We allowed longer time peri-
ods for the change to occur, and counted switching to
different but possibly equipotent regimens and repeated
nonpharmacologic interventions as therapeutic changes.
Patients with additional risk factors for cardiovascular
events were more likely to receive recommended care, sug-
gesting that providers may be targeting patients at highest
risk for hypertensive complications. Alternatively, these
patients may have had better BP control because they were
already engaged in treatment for other conditions. Smok-
ing was the exception to this pattern. Smokers received
lower quality of care even though they are at higher risk
for cardiac complications from hypertension. This is par-
ticularly surprising because cigarette smoking is the only
measured risk factor that directly and immediately affects
Overall process quality scores by demographic and clinical subgroups Figure 1
Overall process quality scores by demographic and clinical subgroupsBMC Cardiovascular Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2261/5/1
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BP, though its effect on long-term hypertension is unclear
[20]. Further research is needed to identify possible expla-
nations, but we hypothesize that physicians provide lower
quality of care to smokers because they perceive them as
unwilling to participate in their own care or less likely to
comply with medical therapy.
As in previous studies of hypertensives who have visited
their physician, just under half of hypertensive patients
had controlled BP. However, patients who received opti-
mal care (i.e., they received all indicated care for which
they were eligible) were more likely to have controlled BP
at the end of the study, supporting the hypothesis that a
broad range of hypertensive process quality is associated
with better intermediate outcomes. The study was not
powered to analyze which specific subcomponents of
hypertensive care were most associated with BP control.
However, because controlled hypertension is correlated
with fewer myocardial infarctions and cerebrovascular
accidents, it also seems likely that better overall care proc-
esses would eventually be associated with fewer complica-
tions from hypertensive care, although we could not
directly test for this.
This process-outcome relationship between hypertensive
care and BP control was observed in almost all subgroups,
but differences in quality were statistically significant pri-
marily in patients without other cardiac risk factors [4].
Unfortunately, our study could not detect small differ-
ences in the relationship between quality of care and BP
control within cardiac risk factor subgroups, and this is
likely to partially explain this finding. However, for
patients with CAD or diabetes, another potential explana-
tion could be a "ceiling effect": diabetic patients received
77% of recommended care and patients with CAD
received 87%, leaving little variation in quality to explain
differences in BP control.
In addition to poor process quality, there are other possi-
ble explanations for the high rates of uncontrolled BP
observed in this study. Even among patients with at least
one medical visit in the last two years, impaired access to
care might be a factor, and this problem was likely worse
in the 863 patients with no visits during the study period
who were not included in the analysis [4]. Among those
included in the study, however, impaired access was likely
a small factor since the average number of provider visits
in the two-year study period was 14 for patients with con-
trolled BP and 12 for those with uncontrolled BP. In addi-
tion, hypertensive quality of care is no better in Canada
despite the presence of universal health insurance in Can-
ada and high prevalence of access problems in the U.S.
[21], suggesting that sub-optimal clinical care processes
are as important as access in explaining our results. Patient
noncompliance has also long been recognized as an
important predictor of poor BP control, but we did not
measure it directly [22].
Our study is the first to examine the relationship between
the quality of hypertensive care and outcomes among a
national population; however, some study limitations
exist beyond those inherent in retrospective medical
record reviews. First, in constructing the indicators, our
expert panel was instructed to rate indicators highly only
if documentation of the process in the medical record was
common and required for good quality care. Nonetheless,
it is possible that documentation differences rather than
true quality differences explain some of the observed var-
iations in process quality or outcomes. A previous study
found that differences in process scores were 10% lower
for medical record abstraction compared to standardized
patients with audiotapes of encounters [23]; thus, our
study may underestimate actual quality of care by that
amount. Second, we chose 140/90 as the threshold for
poor BP control based on expert guidelines in force at the
time of the study, but this threshold could potentially
affect our results. However, sensitivity analyses using a
higher threshold (160/100) and continuous distribution
did not change our results. Later guidelines have sug-
gested lower thresholds for diabetics; our findings
remained consistent when we used 130/85 for this popu-
lation. Third, providers' failure to measure the blood pres-
sure could have caused us to erroneously exclude some
patients from the analysis, though the vast majority of the
studied patients had regular blood pressure measurement.
Fourth, our response rate could have biased our results,
particularly our estimates of overall quality. To account
for this problem, we used standard techniques to adjust
for non-response. Moreover, responders were more likely
to be older and have chronic conditions than non-
responders. Since we found higher quality of care among
these subgroups, it is likely that our estimates represent
upper bounds. Finally, our study does not take into
account the lower threshold for pre-hypertension that was
recently published in JNC-VII [5], since the care we evalu-
ated was delivered prior to this recommendation. Future
research will need to investigate whether the new stand-
ards are associated with better control.
Quality assessment in hypertension is only useful if it is
linked with efforts to improve care. There is some evi-
dence that quality improvement (QI) programs can lead
to BP control among hypertensive patients. Godley has
recently showed that a QI program in a group-model
managed care organization increased BP control from
37% to 49% [24]. Our results can help providers focus on
the processes most likely to improve control and avoid
adverse outcomes.BMC Cardiovascular Disorders 2005, 5:1 http://www.biomedcentral.com/1471-2261/5/1
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Conclusions
We found that the average hypertensive patient in the
United States did not receive one in four essential care
processes, and those with sub-optimal care had worse BP
control. Our data indicate that improvements in processes
of care may lead to better outcomes. While it appears that
providers appropriately focus attention on patients with
additional cardiovascular risk factors, they are under-
treating other hypertensive patients who (as previous
research would suggest) are nonetheless at increased risk
for the same adverse outcomes. Future research should
test if the application of routine measurement of hyper-
tensive process quality in provider groups or plans leads
to improved processes and BP control.
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